DMRA Damora Therapeutics, Inc. - Common Stock
$33.12
价格 · 八月 19, 2026
截至...的财报数据 八月 10, 2026
52周区间
$19–$35
89% of range
分析师评级
BUY
16 analysts
目标价
$45
+35% upside
P/E (TTM)
—
ROE
-167.0%
净利润率
-17981.1%
DMRA 股票快照 价格、市值、P/E、EPS、ROE、负债/权益、52周范围
价格
$33.12
市值
—
P/E (TTM)
—
每股收益 (TTM)
$3.98
营收 (TTM)
—
股息收益率
—
ROE
-167.0%
负债/权益
—
52周区间
$19 – $35
DMRA 股价图表 包含技术指标的日 OHLCV — 平移、缩放和自定义您的视图
Configure
10年表现 收入、净利润、利润率和每股收益趋势
营收与净利润
—
EPS
$3.98
2021-12-31
→
2025-12-31
自由现金流
—
2021-12-31
→
2022-12-31
利润率
-17981.1%
估值 P/E、P/S、P/B、EV/EBITDA 比率 — 该股票是昂贵还是便宜？
指标
5年趋势
DMRA
同行中位数
盈利能力 毛利率、营业利润率和净利率；股本回报率 (ROE)、资产回报率 (ROA)、投入资本回报率 (ROIC)
指标
5年趋势
DMRA
同行中位数
Operating Margin (营业利润率)
-18069.6%
—
Net Profit Margin (净利润率)
-17981.1%
—
ROA
-151.2%
—
ROE
-167.0%
—
ROIC
-87.8%
—
财务健康 债务、流动性、偿付能力 — 资产负债表强度
指标
5年趋势
DMRA
同行中位数
Current Ratio (流动比率)
13.0
—
Quick Ratio (速动比率)
12.8
—
成长 营收、每股收益 (EPS) 和净利润增长：同比、3年复合年增长率 (CAGR)、5年复合年增长率 (CAGR)
指标
5年趋势
DMRA
同行中位数
Revenue YoY (营收同比增长)
38.3%
—
Revenue CAGR 3Y (营收3年复合年增长率)
17.4%
—
资本效率 资产周转率、库存周转率、应收账款周转率
指标
5年趋势
DMRA
同行中位数
DMRA 分析师共识 看涨和看跌分析师观点、12个月价格目标、上涨空间
买入
16 位分析师
- 强烈买入 6 37.5%
- 买入 9 56.2%
- 持有 1 6.2%
- 卖出 0 0.0%
- 强烈卖出 0 0.0%
12个月价格目标
中位数
$45.00
← 低于所有目标
$33.12
最低
$40.00
最高
$51.00
中位数目标
$45.00
+35.9%
平均目标
$44.67
+34.9%
收益历史 每股收益实际值 vs 预估值，惊喜%，达标率，下次财报日期
平均惊喜
1.0%
| 期间 | EPS Actual | EPS 预期 | 惊喜 |
|---|---|---|---|
| 2026年3月31日 | $-0.62 | $-0.40 | -0.22% |
| 2025年12月31日 | $2.70 | $-0.11 | 2.8% |
| 2024年12月31日 | $-5.23 | $-3.03 | -2.2% |
| 2024年9月30日 | $-3.39 | $-4.18 | 0.79% |
| 2024年6月30日 | $-4.00 | $-8.03 | 4.0% |
同行比较（GICS 子行业） 关键指标与行业同行对比
| 股票代码 | 市值 | P/E | 营收同比增长 | 净利润率 | ROE | 毛利率 |
|---|---|---|---|---|---|---|
| DMRA | — | — | 38.3% | -17981.1% | -167.0% | — |
| STOK | $1.87B | -264.5 | 404.5% | -3.7% | -2.0% | — |
| ZBIO | $1.98B | -4.3 | 100.0% | -3777.4% | -156.8% | — |
| AGIO | $1.59B | -3.8 | 48.0% | -764.0% | -32.2% | — |
| TSHA | $1.57B | -16.2 | 17.3% | -1115.3% | -44.0% | — |
| GENB | — | — | — | — | — | — |
| SRPT | $2.26B | -3.0 | 15.6% | -32.5% | -57.1% | — |
| SNDX | $1.84B | -6.4 | 627.8% | -165.6% | -257.1% | — |
| ANAB | — | -105.4 | 157.0% | — | — | — |
| NTLA | $1.05B | -2.4 | 16.9% | -609.8% | -59.5% | — |
完整基本面 所有年度指标 — 损益表、资产负债表、现金流量表
损益表 13
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| R&D Expense | $27M | $6M | $24M | $48M | $38M | $25M | $20M | |
| SG&A Expense | $10M | $10M | $13M | $13M | $14M | $9M | $2M | |
| Operating Expenses | $211M | $22M | $40M | $61M | $52M | $34M | $39M | |
| Operating Income | $-211M | $-22M | $-40M | $-61M | $-52M | $-34M | $39M | |
| Other Non-op | $1M | $862.0K | $2M | $-417.0K | $475.0K | $-1M | $2M | |
| Pretax Income | $-210M | $-21M | $-38M | $-62M | $-52M | $-35M | $-37M | |
| Income Tax | $50.0K | $41.0K | $0 | $0 | $0 | $0 | $0 | |
| Net Income | $-210M | $-21M | $-38M | $-62M | $-52M | $-35M | $-37M | |
| EPS (Basic) | $3.98 | $-18.53 | $-36.08 | $-2.43 | $-2.05 | · | · | |
| EPS (Diluted) | $3.98 | $-18.53 | $-36.08 | $-2.43 | $-2.05 | · | · | |
| Shares (Basic) | 1,363,005 | 1,157,149 | 1,062,873 | 25,409,123 | 25,261,832 | · | · | |
| Shares (Diluted) | 1,363,005 | 1,157,149 | 1,062,873 | 25,409,123 | 25,261,832 | · | · | |
| EBITDA | $-211M | $-22M | $-40M | $-61M | $-52M | $34M | · |
资产负债表 21
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $258M | $14M | $21M | $33M | $63M | $164M | $11M | |
| Short-term Investments | · | · | $12M | $27M | $38M | · | · | |
| Prepaid Expense | $3M | $3M | $4M | $4M | $10M | $6M | $5M | |
| Current Assets | $260M | $17M | $37M | $64M | $110M | $169M | $56M | |
| PP&E (Net) | $36.0K | $57.0K | $78.0K | $357.0K | $203.0K | · | · | |
| PP&E (Gross) | $108.0K | $107.0K | $107.0K | $419.0K | $223.0K | · | · | |
| Accum. Depreciation | $72.0K | $50.0K | $29.0K | $62.0K | $20.0K | · | · | |
| Other Non-current Assets | $104.0K | $163.0K | $1M | $2M | $2M | $1M | · | |
| Total Assets | $261M | $17M | $38M | $73M | $122M | $172M | $57M | |
| Accounts Payable | $444.0K | $377.0K | $2M | $3M | $2M | $3M | $3M | |
| Accrued Liabilities | $2M | $820.0K | $4M | $8M | $3M | $3M | $5M | |
| Current Liabilities | $20M | $1M | $6M | $11M | $5M | $6M | $8M | |
| Capital Leases | $53.0K | $61.0K | $66.0K | $328.0K | $448.0K | $541.0K | $211.0K | |
| Other Non-current Liabilities | $81.0K | $43.0K | · | · | · | · | · | |
| Total Liabilities | $20M | $1M | $6M | $11M | $5M | $6M | $8M | |
| Paid-in Capital | $311M | $292M | $288M | $280M | $274M | $269M | $826.0K | |
| Retained Earnings | $-487M | $-278M | $-256M | $-218M | $-156M | $-104M | $-70M | |
| AOCI | $802.0K | $97.0K | $380.0K | $-244.0K | $-320.0K | $674.0K | $-2M | |
| Stockholders' Equity | $240M | $16M | $32M | $62M | $117M | $165M | $-71M | |
| Liabilities + Equity | $261M | $17M | $38M | $73M | $122M | $172M | $57M | |
| Shares Outstanding | 1,597,321 | 1,316,989 | 1,084,509 | 25,652,392 | 25,261,832 | 25,261,832 | 259,966 |
现金流 10
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Stock-based Comp | $998.0K | $3M | $5M | $6M | $4M | $982.0K | · | |
| Restructuring | · | $968.0K | $3M | · | · | · | · | |
| Operating Cash Flow | $-7M | $-19M | $-37M | $-43M | $-52M | $-38M | $-19M | |
| CapEx | · | · | · | $196.0K | $223.0K | · | · | |
| Investing Cash Flow | $-17M | $12M | $22M | $12M | $-48M | · | $-326.0K | |
| Stock Issued | · | · | $3M | $507.0K | · | · | · | |
| Net Stock Activity | · | · | $3M | $507.0K | · | · | · | |
| Financing Cash Flow | $267M | · | $3M | $507.0K | · | $187M | · | |
| Taxes Paid | $5.0K | · | · | · | · | · | · | |
| Free Cash Flow | · | · | · | $-43M | $-53M | · | · |
盈利能力 7
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Operating Margin | -18069.6% | -2637.4% | -2362.6% | -8477.4% | -33478.8% | · | · | |
| Net Margin | -17981.1% | -2540.2% | -2270.5% | -8535.2% | -33174.4% | · | · | |
| Pretax Margin | -17976.8% | -2535.3% | -2270.5% | -8535.2% | -33174.4% | · | · | |
| EBITDA Margin | -18069.6% | -2637.4% | -2362.6% | -8477.4% | -33478.8% | · | · | |
| ROA | -151.2% | -77.5% | -68.8% | -63.1% | -35.2% | -30.5% | · | |
| ROE | -167.0% | -116.6% | -110.0% | -91.6% | -41.9% | -94.5% | · | |
| ROIC | -87.8% | -140.9% | -123.4% | -99.1% | -44.5% | 20.3% | · |
流动性与偿付能力 2
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Current Ratio | 13.0 | 14.1 | 6.3 | 5.8 | 24.2 | 30.4 | · | |
| Quick Ratio | 12.8 | 11.8 | 5.7 | 5.4 | 22.0 | 29.4 | · |
效率 1
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | · | · |
增长率 2
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 38.3% | -50.0% | 133.9% | 362.8% | · | · | · | |
| Revenue CAGR 3Y | 17.4% | 75.5% | · | · | · | · | · |
估值 (TTM) 2
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $1M | $844.0K | $2M | $722.0K | $156.0K | · | · | |
| Net Income TTM | $-210M | $-21M | $-38M | $-62M | $-52M | $-35M | · |
损益表 13
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| R&D Expense | $26M | $24M | $23M | $1M | $1M | $678.0K | $1M | $1M | $2M | $2M | $3M | $3M | $8M | $10M | $11M | $10M | |
| SG&A Expense | $9M | $7M | $4M | $2M | $2M | $2M | $2M | $3M | $3M | $3M | $3M | $3M | $3M | $3M | $3M | $3M | |
| Operating Expenses | $35M | $31M | $202M | $3M | $3M | $3M | $7M | $4M | $6M | $6M | $7M | $9M | $11M | $13M | $14M | $14M | |
| Operating Income | $-35M | $-31M | $-202M | $-3M | $-3M | $-3M | $-7M | $-4M | $-6M | $-6M | $-7M | $-9M | $-11M | $-13M | $-14M | $-14M | |
| Other Non-op | $4M | $3M | $1M | $23.0K | $-12.0K | $68.0K | $353.0K | $-36.0K | $281.0K | $264.0K | $196.0K | $447.0K | $415.0K | $498.0K | $-544.0K | $-108.0K | |
| Pretax Income | $-31M | $-28M | $-201M | $-3M | $-3M | $-3M | $-7M | $-4M | $-5M | $-5M | $-6M | $-8M | $-11M | · | · | · | |
| Income Tax | $255.0K | $42.0K | $44.0K | $0 | $4.0K | $2.0K | $-8.0K | $7.0K | $42.0K | · | · | · | · | · | · | · | |
| Net Income | $-31M | $-28M | $-201M | $-3M | $-3M | $-3M | $-7M | $-4M | $-5M | $-5M | $-6M | $-8M | $-11M | $-13M | $-14M | $-14M | |
| EPS (Basic) | $-0.39 | $-0.62 | $10.86 | $-2.36 | $-2.60 | $-1.92 | $-5.17 | $-3.39 | $-4.92 | $-5.05 | $-27.66 | $-7.50 | $-0.41 | $-0.51 | $-0.55 | $-0.54 | |
| EPS (Diluted) | $-0.39 | $-0.62 | $10.86 | $-2.36 | $-2.60 | $-1.92 | $-5.17 | $-3.39 | $-4.92 | $-5.05 | $-27.66 | $-7.50 | $-0.41 | $-0.51 | $-0.55 | $-0.54 | |
| Shares (Basic) | 61,117,057 | 34,299,182 | -2,608,598 | 1,327,039 | 1,322,553 | 1,322,011 | -2,156,960 | 1,144,978 | 1,084,622 | 1,084,509 | -52,069,296 | 1,084,191 | 26,375,076 | 25,672,902 | -50,614,809 | 25,491,786 | |
| Shares (Diluted) | 61,117,057 | 34,299,182 | -2,608,598 | 1,327,039 | 1,322,553 | 1,322,011 | -2,156,960 | 1,144,978 | 1,084,622 | 1,084,509 | -52,069,296 | 1,084,191 | 26,375,076 | 25,672,902 | -50,614,809 | 25,491,786 | |
| EBITDA | $-35M | $-31M | · | $-3M | $-3M | $-3M | · | $-4M | $-6M | $-6M | · | $-9M | $-11M | $-13M | · | $-14M |
资产负债表 22
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $541M | $533M | $258M | $8M | $10M | $12M | $14M | $20M | $23M | $21M | $21M | $23M | $23M | $25M | $33M | $28M | |
| Short-term Investments | · | · | · | · | · | · | · | · | · | $6M | $12M | $21M | $29M | $28M | $27M | $41M | |
| Prepaid Expense | $3M | $3M | $3M | $2M | $3M | $3M | $3M | $2M | $2M | $3M | $4M | $3M | $3M | $4M | $4M | $2M | |
| Current Assets | $544M | $535M | $260M | $10M | $13M | $15M | $17M | $21M | $25M | $31M | $37M | $47M | $55M | $57M | $64M | $71M | |
| PP&E (Net) | · | · | $36.0K | $41.0K | $47.0K | $52.0K | $57.0K | $62.0K | $67.0K | $73.0K | $78.0K | $125.0K | $328.0K | $345.0K | $357.0K | $338.0K | |
| PP&E (Gross) | · | · | $108.0K | $108.0K | $108.0K | $107.0K | $107.0K | $107.0K | $106.0K | $107.0K | $107.0K | $430.0K | $425.0K | $425.0K | $419.0K | $379.0K | |
| Accum. Depreciation | · | · | $72.0K | $67.0K | $61.0K | $55.0K | $50.0K | $45.0K | $39.0K | $34.0K | $29.0K | $305.0K | $97.0K | $80.0K | $62.0K | $41.0K | |
| Other Non-current Assets | $48.0K | $34.0K | $0 | $837.0K | $542.0K | $317.0K | $163.0K | $2M | $2M | $2M | $1M | $2M | $2M | $2M | $2M | $3M | |
| Total Assets | $544M | $535M | $261M | $11M | $14M | $15M | $17M | $23M | $27M | $32M | $38M | $50M | $59M | $65M | $73M | $82M | |
| Accounts Payable | $3M | $819.0K | $444.0K | $520.0K | $756.0K | $354.0K | $377.0K | $503.0K | $724.0K | $2M | $2M | $4M | $6M | $4M | $3M | $2M | |
| Accrued Liabilities | $9M | $6M | $2M | $2M | $2M | $1M | $820.0K | $2M | $3M | $3M | $4M | $8M | $9M | $11M | $8M | $7M | |
| Current Liabilities | $28M | $24M | $20M | $3M | $3M | $2M | $1M | $2M | $4M | $4M | $6M | $13M | $15M | $14M | $11M | $9M | |
| Capital Leases | · | · | $53.0K | $57.0K | $60.0K | $60.0K | $61.0K | · | · | · | $66.0K | $112.0K | $206.0K | $234.0K | $328.0K | $440.0K | |
| Other Non-current Liabilities | $27.0K | $27.0K | $28.0K | $49.0K | $49.0K | $45.0K | $43.0K | · | · | · | · | · | · | · | · | · | |
| Total Liabilities | $28M | $24M | $20M | $3M | $3M | $2M | $1M | $2M | $4M | $4M | $6M | $13M | $15M | $14M | $11M | $9M | |
| Common Stock | $1.0K | $1.0K | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| Paid-in Capital | $932M | $894M | $311M | $292M | $292M | $292M | $292M | $291M | $290M | $289M | $288M | $287M | $285M | $281M | $280M | $278M | |
| Retained Earnings | $-546M | $-515M | $-487M | $-287M | $-283M | $-280M | $-278M | $-271M | $-267M | $-262M | $-256M | $-250M | $-241M | $-231M | $-218M | $-204M | |
| AOCI | $732.0K | $754.0K | $802.0K | $823.0K | $809.0K | $300.0K | $97.0K | $665.0K | $197.0K | $326.0K | $380.0K | $46.0K | $-137.0K | $-127.0K | $-244.0K | $-2M | |
| Stockholders' Equity | $516M | $512M | $240M | $8M | $11M | $14M | $16M | $21M | $24M | $28M | $32M | $37M | $44M | $50M | $62M | $73M | |
| Liabilities + Equity | $544M | $535M | $261M | $11M | $14M | $15M | $17M | $23M | $27M | $32M | $38M | $50M | $59M | $65M | $73M | $82M | |
| Shares Outstanding | 61,734,601 | 60,303,212 | 1,597,321 | 1,327,212 | 1,324,560 | 1,322,359 | 1,316,989 | 1,253,843 | 27,121,030 | 27,112,697 | 1,084,509 | 27,112,697 | 27,021,899 | 25,673,474 | 25,652,392 | 25,581,029 |
现金流 9
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock-based Comp | $6M | $3M | $483.0K | $164.0K | $172.0K | $179.0K | $308.0K | $681.0K | $891.0K | $1M | $1M | $1M | $1M | $1M | $1M | $1M | |
| Restructuring | · | · | · | · | · | · | $0 | $0 | $-2M | $3M | · | $3M | · | · | · | · | |
| Operating Cash Flow | $-22M | $-21M | $566.0K | $-3M | $-2M | $-2M | $-5M | $-4M | $-4M | $-6M | $-11M | $-8M | $-8M | $-9M | $-11M | $-10M | |
| CapEx | · | · | · | · | · | · | · | · | · | · | · | · | · | · | $41.0K | $138.0K | |
| Investing Cash Flow | · | · | · | · | · | · | $0 | $0 | $6M | $6M | $10M | $8M | $3M | $1M | $14M | $8M | |
| Stock Issued | · | · | · | · | · | · | · | · | · | · | $0 | $171.0K | $3M | $23.0K | $65.0K | $424.0K | |
| Net Stock Activity | · | · | · | · | · | · | · | · | · | · | · | · | · | $23.0K | · | · | |
| Financing Cash Flow | $30M | $296M | · | · | · | · | · | · | · | · | $0 | $171.0K | $3M | $23.0K | $65.0K | $424.0K | |
| Taxes Paid | · | · | $0 | $0 | $3.0K | $2.0K | · | · | · | · | · | · | · | · | · | · |
盈利能力 7
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -862.1% | -1003.6% | · | -7514.3% | -6842.0% | -3512.2% | · | -2630.1% | -2618.3% | -2233.8% | · | -1814.6% | -2524.7% | -3108.8% | · | -6163.8% | |
| Net Margin | -768.0% | -905.0% | · | -7459.5% | -6874.0% | -3423.0% | · | -2659.6% | -2506.1% | -2131.1% | · | -1720.1% | -2430.8% | -2994.0% | · | -6212.7% | |
| Pretax Margin | -761.7% | -903.6% | · | -7459.5% | -6866.0% | -3420.3% | · | -2654.8% | -2486.4% | · | · | · | · | · | · | · | |
| EBITDA Margin | -862.1% | -1003.6% | · | -7514.3% | -6842.0% | -3512.2% | · | -2630.1% | -2618.3% | -2233.8% | · | -1814.6% | -2524.7% | -3108.8% | · | -6163.8% | |
| ROA | -11.2% | -10.1% | · | -18.4% | -16.8% | -10.6% | · | -10.6% | -12.4% | -11.3% | · | -12.3% | -14.2% | -15.0% | · | -12.6% | |
| ROE | -11.8% | -10.6% | · | -21.6% | -19.9% | -12.1% | · | -13.3% | -15.9% | -14.0% | · | -14.8% | -16.7% | -17.1% | · | -13.6% | |
| ROIC | -6.8% | -6.0% | · | -39.4% | -31.3% | -19.0% | · | -18.4% | -23.8% | · | · | · | · | · | · | · |
流动性与偿付能力 2
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 19.7 | 22.5 | · | 3.7 | 5.0 | 9.6 | · | 8.7 | 6.8 | 7.1 | · | 3.7 | 3.7 | 4.1 | · | 8.0 | |
| Quick Ratio | 19.6 | 22.4 | · | 2.9 | 3.9 | 7.7 | · | 8.1 | 6.2 | 6.3 | · | 3.5 | 3.5 | 3.8 | · | 7.8 |
效率 1
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 |
估值 (TTM) 8
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $7M | $3M | · | $312.0K | $483.0K | $690.0K | · | $1M | $1M | $2M | · | $2M | $1M | $872.0K | · | $473.0K | |
| Net Income TTM | $-66M | $-37M | · | $-13M | $-15M | $-17M | · | $-23M | $-30M | $-37M | · | $-46M | $-54M | $-61M | · | $-60M | |
| Market Cap | $1.61B | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| P/E | -4.4 | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| P/S | 222.4 | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| P/B | 3.1 | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| P / Tangible Book | 3.1 | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| Earnings Yield | -22.9% | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · |
财务报表 损益表、资产负债表、现金流量表 — 年度，近5年
损益表
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| 营业利润率 % | -18069.6% | -2637.4% | -2362.6% | -8477.4% | -33478.8% |
| 净收入 | $-210M | $-21M | $-38M | $-62M | $-52M |
| 稀释后每股收益 (EPS) | $3.98 | $-18.53 | $-36.08 | $-2.43 | $-2.05 |
资产负债表
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| 流动比率 | 13.0 | 14.1 | 6.3 | 5.8 | 24.2 |
| 速动比率 | 12.8 | 11.8 | 5.7 | 5.4 | 22.0 |
现金流
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| 自由现金流 | — | — | — | $-43M | $-53M |
我的指标 您的个人关注列表 — 来自完整基本面的选定行
📊
选择对您重要的指标 — 点击上方完整基本面中任意行的 ➕。
您的选择已保存，并会跟随您浏览所有股票。
公司内部人士 25 位内幕人士 · 11 位高管 · 14 位董事
| 内部人士 | 角色 | 上次活动 | 持股数量 | 买入 12个月 | 卖出 12个月 | 净额 12个月 |
|---|---|---|---|---|---|---|
| Jennifer Jarrett | President and Chief Executive Officer | 2026年3月30日 A | 500000 | 0 | 0 | $0 |
| Hans T. Schambye | Chief Executive Officer | 2026年1月2日 M | 4682 | 0 | 1 | $-14966 |
| Lori Firmani | Chief Financial Officer | 2026年1月2日 M | 931 | 0 | 1 | $-2890 |
| Jonathan Freve | Chief Financial Officer | 2024年1月3日 A | 12000 | 0 | 0 | $0 |
| Sherwin Sattarzadeh | Chief Operating Officer | 2026年1月5日 A | 190376 | 0 | 0 | $0 |
| Anders Pedersen | Chief Operating Officer | 2023年1月4日 A | 3746 | 0 | 0 | $0 |
| Garrett Winslow | General Counsel | 2026年7月3日 M | 2289 | 0 | 2 | $-12797 |
| Becker L. Hewes | Chief Medical Officer | 2026年1月5日 A | 264629 | 0 | 0 | $0 |
| Matthew Kronmiller | EVP Strategy and CBO | 2025年1月3日 A | — | 0 | 0 | $0 |
| Stephanie Oestreich | Chief Business Officer | 2023年1月4日 A | — | 0 | 0 | $0 |
| Bertil Lindmark | Chief Medical Officer | 2023年1月4日 A | 16604 | 0 | 0 | $0 |
| Julianne Bruno | 董事 | 2026年3月23日 A | 137032 | 0 | 0 | $0 |
| Christopher W. Cain | 董事 | 2026年3月23日 A | — | 0 | 0 | $0 |
| Cameron Turtle | 董事 | 2026年3月23日 A | — | 0 | 0 | $0 |
| Michael Landsittel | 董事 | 2026年3月23日 A | — | 0 | 0 | $0 |
| Anne Prener | 董事 | 2025年6月18日 A | — | 0 | 0 | $0 |
| Amy B Wechsler | 董事 | 2025年6月18日 A | — | 0 | 0 | $0 |
| Jayson Donald Alexander Dallas | 董事 | 2025年6月18日 A | — | 0 | 0 | $0 |
| Amit Munshi | 董事 | 2025年6月18日 A | 4793 | 0 | 0 | $0 |
| David Shapiro | 董事 | 2025年6月18日 A | — | 0 | 0 | $0 |
| Carl Goldfischer | 董事 | 2025年6月18日 A | 19432 | 0 | 0 | $0 |
| Chau Quang Khuong | 董事 | 2023年6月14日 A | 1031811 | 0 | 0 | $0 |
| Stephan Christgau | 董事 | 2020年11月2日 C | 546136 | 0 | 0 | $0 |
| Novo Holdings A/S | 10% 所有者 | 2020年11月2日 C | 2497791 | 0 | 0 | $0 |
| Andrew Cheng | — | 2026年8月12日 A | — | 0 | 0 | $0 |
来自SEC表格3/4/5申报的内部人士；净额=仅公开市场买卖
激进投资者及 5%+ 股东 3 持仓
提交了 SEC Schedule 13D 的投资者 — 持有超过 5% 的受益所有权，意图影响发行人（激进股东持股、董事会活动、并购）。每一行显示该申报人持仓的最新已知状态。
| 申报人 | 已申报 | 持股 | 状态 | 目的 | 申报 |
|---|---|---|---|---|---|
| Fairmount Funds Management LLC, Fairmount Healthcare Fund II L.P., Fairmount Healthcare Co-Invest V L.P., Peter Evan Harwin, Tomas Kiselak ×2 申报 | 2026年2月11日 | 19.99% | 修订 | — | SEC |
| Novo Holdings A/S ×6 申报 | 2025年10月9日 | 0.00% | 修订 | — | SEC |
| OrbiMed Advisors LLC, OrbiMed Advisors Israel II Limited, OrbiMed Israel GP II, L.P., OrbiMed Capital GP VII LLC, OrbiMed Genesis GP LLC, OrbiMed Capital LLC ×7 申报 | 2023年9月18日 | — | 初始申报 | — | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
ETF持仓 由 12 只交易所交易基金持有
权重仅反映直接股权持仓（N-PORT）；杠杆基金或基于衍生品的基金可能持有未显示的额外掉期敞口。
| 基金 | 权重 | 单位 | 截至 | 来源 |
|---|---|---|---|---|
| IWO · iShares Trust | 0.07% | 331064 SH | 2026年8月8日 | 每日 |
| VTWG · VANGUARD SCOTTSDALE FUNDS | 0.06% | 39408 SH | 2026年8月8日 | 每日 |
| IWM · iShares Trust | 0.05% | 1337645 SH | 2026年8月8日 | 每日 |
| VTWO · VANGUARD SCOTTSDALE FUNDS | 0.04% | 307241 SH | 2026年8月8日 | 每日 |
| IWN · iShares Trust | 0.03% | 152816 SH | 2026年8月8日 | 每日 |
| VTWV · VANGUARD SCOTTSDALE FUNDS | 0.03% | 14454 SH | 2026年8月8日 | 每日 |
| OMFS · Invesco Exchange-Traded Self-Inde... | 0.03% | 2758 SH | 2026年8月8日 | 每日 |
| ISCB · iShares Trust | 0.02% | 2013 SH | 2026年8月8日 | 每日 |
| WSML · iShares Trust | 0.01% | 2534 SH | 2026年8月8日 | 每日 |
| VXF · VANGUARD INDEX FUNDS | 0.01% | 212600 SH | 2026年8月8日 | 每日 |
| IWV · iShares Trust | 0.00% | 14147 SH | 2026年8月8日 | 每日 |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0.00% | 4396 SH | 2026年8月8日 | 每日 |